Geoffrey Chong

10PUBLICATIONS
46CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Animal immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 29, 2026
Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial Abstracts.

|Apr 08, 2026
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

Arina Martynchyk, Geoffrey Chong, Richard Khor

|Jun 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.

Jack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee

|Jun 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

Eliza A Hawkes, Jodie B Palmer, Richard Khor

|Jan 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Allison Barraclough, Sze Ting Lee, Melinda Burgess

|Jan 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review.

Luke Wang, Eliza Chung, Cameron Wellard

Pageof 2

Frequent Collaborators

10 joint publications

Eliza A Hawkes

5 joint publications

Allison Barraclough

4 joint publications

Colm Keane

4 joint publications

Arina Martynchyk